Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
USA001, Gainesville, Florida, United States
USA016, Augusta, Georgia, United States
USA006, Cleveland, Ohio, United States
USA002, New York, New York, United States
ESP002, Barcelona, Spain
ESP004, Madrid, Spain
ESP003, Barcelona, Spain
USA014, Saint Petersburg, Florida, United States
USA084, Sebastian, Florida, United States
USA067, Tampa, Florida, United States
USA039, Kissimmee, Florida, United States
USA029, Newport Beach, California, United States
USA103, Plantation, Florida, United States
MHAT "Dr IvanSeliminski"-Sliven, Sliven, Bulgaria
Cardioart Medical Center, Stara Zagora, Bulgaria
Sjællands Universitetshospital, Roskilde, Roskilde, Denmark